Immunovant, Inc. (NASDAQ: IMVT) reported Q3 EPS of ($0.36), $0.07 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Immunovant, Inc. (IMVT) click here.